Back to Search
DR. JOSHUA ANDREW BLATTER MD
MD
Pediatric Pulmonology Physician
NPI: 1316109168IndividualAccepts Medicare
Specialties, Licenses & Credentials
Pediatrics Physician
Pediatrics
Code: 208000000X
2014021226(MO)
Pediatric Pulmonology PhysicianPrimary
Pediatrics — Pediatric Pulmonology
Code: 2080P0214X
2014021226(MO)
Education
UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE
Class of 2008
Research & Publications (20)
Malignant peritoneal mesothelioma-Results from the International Expanded Access Program using pemetrexed alone or in combination with a platinum agent.
PMID 19042053·Lung Cancer·2009
3-trial
The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies.
PMID 19221167·Oncologist·2009
3-trial
Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaïve patients with malignant pleural mesothelioma: results of the International Expanded Access Program.
PMID 18594322·J Thorac Oncol·2008
3-trial
Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma.
PMID 18375898·J Clin Oncol·2008
3-trial
Correlations of mRNA expression and in vitro chemosensitivity to enzastaurin in freshly explanted human tumor cells.
PMID 18000644·Invest New Drugs·2008
8-other
Single-agent pemetrexed for chemonaïve and pretreated patients with malignant pleural mesothelioma: results of an International Expanded Access Program.
PMID 18594323·J Thorac Oncol·2008
4-observational
A randomized phase II trial of pemetrexed plus irinotecan (ALIRI) versus leucovorin-modulated 5-FU plus irinotecan (FOLFIRI) in first-line treatment of locally advanced or metastatic colorectal cancer.
PMID 18334829·Oncology·2007
3-trial
Assessment of the value of confirming responses in clinical trials in oncology.
PMID 16026690·Eur J Cancer·2005
8-other
Pemetrexed combined with oxaliplatin or carboplatin as first-line treatment in advanced non-small cell lung cancer: a multicenter, randomized, phase II trial.
PMID 15701857·Clin Cancer Res·2005
3-trial
Pemetrexed: mRNA expression of the target genes TS, GARFT and DHFR correlates with the in vitro chemosensitivity of human solid tumors.
PMID 16372519·Int J Clin Pharmacol Ther·2005
8-other
Enzastaurin and pemetrexed exert synergistic antitumor activity in thyroid cancer cell lines in vitro.
PMID 16372535·Int J Clin Pharmacol Ther·2005
4-observational
Preclinical evaluation of a radiosensitizing effect of gemcitabine in p53 mutant and p53 wild type bladder cancer cells.
PMID 12597983·Urology·2003
7-preclinical
A phase II trial of pemetrexed in patients with metastatic renal cancer.
PMID 14578684·Invest New Drugs·2003
3-trial
Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma.
PMID 12697881·J Clin Oncol·2003
3-trial
Gemcitabine monotherapy as second-line treatment in cisplatin-refractory transitional cell carcinoma - prognostic factors for response and improvement of quality of life.
PMID 11893883·Onkologie·2002
3-trial
Interaction of pemetrexed disodium (ALIMTA, multitargeted antifolate) and irradiation in vitro.
PMID 11955753·Int J Radiat Oncol Biol Phys·2002
8-other
Gemcitabine plus etoposide in chemonaive extensive disease small-cell lung cancer: a multi-centre phase II study.
PMID 11484961·Ann Oncol·2001
3-trial
Apoptosis and changes in glucose transport early after treatment of Morris hepatoma with gemcitabine.
PMID 11357491·Eur J Nucl Med·2001
7-preclinical
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 1 CHILDRENS PL, DIV PED ALLERGY/IMMUNO/PULMO
SAINT LOUIS, MO 63110 - Phone
- (314) 454-2694
Quick Facts
- NPI
- 1316109168
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 2
- Locations
- 1
- Years in Practice
- 18
- Publications
- 20
Are you this provider?
Claim Your Profile